Ignite Creation Date:
2025-12-24 @ 7:36 PM
Ignite Modification Date:
2026-04-12 @ 12:52 PM
Study NCT ID:
NCT02107703
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-21
First Post:
2014-04-04
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Sponsor:
Eli Lilly and Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-07-22
Start Date Type:
ACTUAL
Primary Completion Date:
2017-02-14
Primary Completion Date Type:
ACTUAL
Completion Date:
2027-12
Completion Date Type:
ESTIMATED
First Submit Date:
2014-04-04
First Submit QC Date:
None
Study First Post Date:
2014-04-08
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-02-12
Results First Submit QC Date:
None
Results First Post Date:
2018-03-13
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-17
Last Update Post Date:
2025-10-21
Last Update Post Date Type:
ESTIMATED